RE-VERSE-AD 1321.3 A phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with diabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to test and investigation drug called idarucizumab to see if it is safe and will reverse the bleeding effect of dabigatran.
Description
The purpose of this study is to test and investigation drug called idarucizumab to see if it is safe and will reverse the bleeding effect of dabigatran.
Details
| Condition | Uncontrolled bleeding |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX5130 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.